Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their ...

On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...

Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

With another quarter of growth in the books, Swiss CDMO Lonza is continuing to regain its forward momentum as it seeks to ...

Three years ago, the FDA found so many violations at a Nephron Pharmaceuticals manufacturing facility that the U.S. | Nephron ...

For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

In a new white paper, Havas Lynx lays out ways in which pharma marketers can—and should, according to the health comms agency ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

Cambrex revealed plans to spend $120 million to expand its Iowa manufacturing operations on the heels of a report last month ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.